Advertisement

Irish Journal of Medical Science (1971 -)

, Volume 185, Issue 2, pp 319–326 | Cite as

Get the GIST? An overview of gastrointestinal stromal tumours

  • G. A. Watson
  • D. Kelly
  • M. Melland-Smith
  • J. Gleeson
  • G. McEntee
  • C. M. Kelly
  • J. A. McCaffrey
Review Article

Abstract

GISTs are the most common mesenchymal neoplasms of the gastrointestinal tract. The last 20 years have been revolutionary in the understanding of these tumours and began with the discovery of c-KIT, a proto oncogene that when mutated forms the molecular basis for the growth and development of these malignancies. Surgery was previously considered to be the only treatment modality in both local and advanced disease, however, the introduction of immunotherapy agents such as tyrosine kinase inhibitors has had profound effects on how we now approach and manage these tumours. These novel agents have significantly reduced the frequency of disease recurrence and dramatically improved survival, and serve as a model for the study of targeted therapies in other solid tumors. We present a review of gastrointestinal stromal tumours and consider the current evidence based detection and management of these unique tumors.

Keywords

Gastrointestinal stromal tumors (GIST) c-KIT Imatinib mesylate Review 

References

  1. 1.
    Connolly EM, Gaffney E, Reynolds JV (2003) Gastrointestinal stromal tumours. Br J Surg 90:1178–1186CrossRefPubMedGoogle Scholar
  2. 2.
    Rubin BP, Fletcher JA, Fletcher CD (2000) Molecular insights into the histogenesis and pathogenesis of gastrointestinal stromal tumors. Int J Surg Pathol 8:5CrossRefPubMedGoogle Scholar
  3. 3.
    Miettinen M, Lasota J (2001) Gastrointestinal stromal tumors—definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 438:1CrossRefPubMedGoogle Scholar
  4. 4.
    Miettinen M, Sarlomo-Rikala M, Lasota J (1999) Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 30:1213CrossRefPubMedGoogle Scholar
  5. 5.
    Medeiros F, Corless CL, Duensing A, Hornick JL, Oliveira AM, Heinrich MC, Fletcher JA, Fletcher CD (2004) KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 28:889CrossRefPubMedGoogle Scholar
  6. 6.
    Tran T, Davila JA, El-Serag HB (2005) The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol 100:162CrossRefPubMedGoogle Scholar
  7. 7.
    Nilsson B, Bümming P, Meis-Kindblom JM, Odén A, Dortok A, Gustavsson B, Sablinska K, Kindblom LG (2005) Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era—a population-based study in western Sweden. Cancer 103:821CrossRefPubMedGoogle Scholar
  8. 8.
    Tryggvason G, Gíslason HG, Magnússon MK, Jónasson JG (2005) Gastrointestinal stromal tumors in Iceland, 1990–2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer 117:289CrossRefPubMedGoogle Scholar
  9. 9.
    Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O’Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33:459CrossRefPubMedGoogle Scholar
  10. 10.
    Rammohan A, Sathyanesan J, Rajendran K, Pitchaimuthu A, Perumal SK, Srinivasan U, Ramasamy R, Palaniappan R, Govindan M (2013) A gist of gastrointestinal stromal tumors: a review. World J Gastrointest Oncol. 5:102–112CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Goettsch WG, Bos SD, Breekveldt-Postma N, Casparie M, Herings RM, Hogendoorn PC (2005) Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer 41:2868–2872CrossRefPubMedGoogle Scholar
  12. 12.
    Janeway KA, Liegl B, Harlow A, Le C, Perez-Atayde A, Kozakewich H, Corless CL, Heinrich MC, Fletcher JA (2007) Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. Cancer Res 67:9084CrossRefPubMedGoogle Scholar
  13. 13.
    Miettinen M, Fetsch JF, Sobin LH, Lasota J (2006) Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol 30:90CrossRefPubMedGoogle Scholar
  14. 14.
    Agaram NP, Laquaglia MP, Ustun B, Guo T, Wong GC, Socci ND, Maki RG, DeMatteo RP, Besmer P, Antonescu CR (2008) Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res 14:3204CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Mazur MT, Clark HB (1983) Gastric stromal tumors: reappraisal of histogenesis. Am J Surg Pathol 7:507–519CrossRefPubMedGoogle Scholar
  16. 16.
    Schaldenbrand JD, Appelman HD (1984) Solitary solid stromal gastrointestinal tumors in von Recklinghausen’s disease with minimal smooth muscle differentiation. Hum Pathol 15(3):229–232CrossRefPubMedGoogle Scholar
  17. 17.
    Sircar K, Hewlett BR, Huizinga JD, Chorneyko K, Berezin I, Riddell RH (1999) Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. Am J Surg Pathol 23:377CrossRefPubMedGoogle Scholar
  18. 18.
    Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279(5350):577–580CrossRefPubMedGoogle Scholar
  19. 19.
    Ghanem N, Altehoefer C, Furtwangler A, Winterer J, Schäfer O, Springer O, Kotter E, Langer M (2003) Computed tomography in gastrointestinal stromal tumors. Eur Radiol 13(7):1669–1678CrossRefPubMedGoogle Scholar
  20. 20.
    Akahoshi K, Sumida Y, Matsui N, Oya M, Akinaga R, Kubokawa M, Motomura Y, Honda K, Watanabe M, Nagaie T (2007) Preoperative diagnosis of gastrointestinal stromal tumor by endoscopic ultrasound-guided fine needle aspiration. World J Gastroenterol 13:2077–2082CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Shojaku H, Futatsuya R, Seto H, Tajika S, Matsunou H (1997) Malignant gastrointestinal stromal tumor of the small intestine: radiologic-pathologic correlation. Radiat Med 15(3):189–192PubMedGoogle Scholar
  22. 22.
    Sepe PS, Brugge WR (2009) A guide for the diagnosis and management of gastrointestinal stromal cell tumors. Nat Rev Gastroenterol Hepatol 6:363–371CrossRefPubMedGoogle Scholar
  23. 23.
    Kamiyama Y, Aihara R, Nakabayashi T, Mochiki E, Asao T, Kuwano H, Oriuchi N, Endo K (2005) 18F-fluorodeoxyglucose positron emission tomography: useful technique for predicting malignant potential of gastrointestinal stromal tumors. World J Surg 29:1429CrossRefPubMedGoogle Scholar
  24. 24.
    Miettinen M, Lasota J (2006) Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 23:70CrossRefPubMedGoogle Scholar
  25. 25.
    Burkill GJ, Badran M, Al-Muderis O, Meirion Thomas J, Judson IR, Fisher C, Moskovic EC (2003) Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread. Radiology 226:527CrossRefPubMedGoogle Scholar
  26. 26.
    Joensuu H (2008) Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 39(10):1411–1419CrossRefPubMedGoogle Scholar
  27. 27.
    Miettinen M, Sobin LH, Lasota J (2005) Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 29:52CrossRefPubMedGoogle Scholar
  28. 28.
    Miettinen M, Makhlouf H, Sobin LH, Lasota J (2006) Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 30:477CrossRefPubMedGoogle Scholar
  29. 29.
    DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF (2000) Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231:51CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Corless CL, Ballman KV, Antonescu CR, Kolesnikova V, Maki RG, Pisters PW, Blackstein ME, Blanke CD, Demetri GD, Heinrich MC, von Mehren M, Patel S, McCarter MD, Owzar K, DeMatteo RP (2014) Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. J Clin Oncol 32:1563CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Gold JS, Gönen M, Gutiérrez A, Broto JM, García-del-Muro X, Smyrk TC, Maki RG, Singer S, Brennan MF, Antonescu CR, Donohue JH, DeMatteo RP (2009) Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 10:1045CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Benjamin RS (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25:1753–1759CrossRefPubMedGoogle Scholar
  33. 33.
    Otani Y, Furukawa T, Yoshida M, Saikawa Y, Wada N, Ueda M, Kubota T, Mukai M, Kameyama K, Sugino Y, Kumai K, Kitajima M (2006) Operative indications for relatively small (2–5 cm) gastrointestinal stromal tumor of the stomach based on analysis of 60 operated cases. Surgery 139:484CrossRefPubMedGoogle Scholar
  34. 34.
    Beham AW, Schaefer IM, Schüler P, Cameron S, Ghadimi BM (2012) Gastrointestinal stromal tumors. Int J Colorectal Dis 27:689–700CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Pidhorecky I, Cheney RT, Kraybill WG, Gibbs JF (2000) Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Ann Surg Oncol 7:705–712CrossRefPubMedGoogle Scholar
  36. 36.
    Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD, Ryan CW, von Mehren M, Blanke CD, Rankin C, Benjamin RS, Bramwell VH, Demetri GD, Bertagnolli MM, Fletcher JA (2008) Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 26:5360CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT, Blay JY, Leyvraz S, Stul M, Casali PG, Zalcberg J, Verweij J, Van Glabbeke M, Hagemeijer A, Judson I, EORTC Soft Tissue and Bone Sarcoma Group, Italian Sarcoma Group, Australasian GastroIntestinal Trials Group (2006) KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42:1093CrossRefPubMedGoogle Scholar
  38. 38.
    ESMO/European Sarcoma Network Working Group (2012) Gastrointestinal stromal tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl 7):vii49Google Scholar
  39. 39.
    Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, Pisters PW, Raut CP, Riedel RF, Schuetze S (2010) NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw 8(Suppl 2):S1–S41 (quiz S42–S44) PubMedPubMedCentralGoogle Scholar
  40. 40.
    Wang D, Zhang Q, Blanke CD, Demetri GD, Heinrich MC, Watson JC, Hoffman JP, Okuno S, Kane JM, von Mehren M (2012) Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. Ann Surg Oncol 19:1074–1080CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Eisenberg BL, Harris J, Blanke CD, Demetri GD, Heinrich MC, Watson JC, Hoffman JP, Okuno S, Kane JM, von Mehren M (2009) Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol 99:42–47CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Van Glabbeke M, Verweij J, Casali PG, Simes J, Le Cesne A, Reichardt P, Issels R, Judson IR, van Oosterom AT, Blay JY (2006) Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG). Eur J Cancer 42:2277CrossRefPubMedGoogle Scholar
  43. 43.
    Huguet KL, Rush RM Jr, Tessier DJ, Schlinkert RT, Hinder RA, Grinberg GG, Kendrick ML, Harold KL (2008) Laparoscopic gastric gastrointestinal stromal tumor resection: the mayo clinic experience. Arch Surg 143:587CrossRefPubMedGoogle Scholar
  44. 44.
    Nishimura J, Nakajima K, Omori T, Takahashi T, Nishitani A, Ito T, Nishida T (2007) Surgical strategy for gastric gastrointestinal stromal tumors: laparoscopic vs. open resection. Surg Endosc 21:875CrossRefPubMedGoogle Scholar
  45. 45.
    Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H, Corless C, Debiec-Rychter M, DeMatteo R, Ettinger D, Fisher G, Fletcher C, Gronchi A, Hohenberger P, Hughes M, Joensuu H, Judson I, Le Cesne A, Maki R, Morse M, Pappo A, Pisters P, Raut C, Reichardt P, Tyler D, Van der Abbeele A, von Mehren M, Wayne J, Zalcbers J (2007) NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)—update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 5(Suppl 2):S1–S29 (quiz S30) PubMedGoogle Scholar
  46. 46.
    DeMatteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K, American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team (2009) Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373:1097CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Casali P, Le Cesne A, Velasco AP, Kotasek D, Rutkowski P, Hohenberger P, Fumagalli E, Judson IR, Italiano A, Broto JM, Gronchi A, Paolo Dei Tos A, Marreaud S, Van Der Graaf WTA, Zalcberg JR, Litière S, Blay JY (2013) Imatinib failure-free survival (IFS) in patients with localized gastrointestinal stromal tumors (GIST) treated with adjuvant imatinib (IM): the EORTC/AGITG/FSG/GEIS/ISG randomized controlled phase III trial (abstract). J Clin Oncol 31(Suppl 15):10500Google Scholar
  48. 48.
    Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Monge OR, Bono P, Kallio R, Vehtari A, Leinonen M, Alvegård T, Reichardt P (2012) One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 307:1265CrossRefPubMedGoogle Scholar
  49. 49.
    von Mehren M, Watson JC (2009) Perioperative tyrosine kinase inhibitors for GIST: standard… or an idea that needs further investigation? Oncology (Williston Park) 23:65Google Scholar
  50. 50.
    Fiore M, Palassini E, Fumagalli E, Pilotti S, Tamborini E, Stacchiotti S, Pennacchioli E, Casali PG, Gronchi A (2009) Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). Eur J Surg Oncol 35:739–745CrossRefPubMedGoogle Scholar
  51. 51.
    Carboni F, Carlini M, Scardamaglia F, Santoro E, Boschetto A, Castelli M, Marandino F, Santoro E (2003) Gastrointestinal stromal tumors of the stomach. A ten-year surgical experience. J Exp Clin Cancer Res 22:379PubMedGoogle Scholar
  52. 52.
    Chacón M, Roca E, Huertas E, Loria FS, Domenechini E (2005) CASE 3. Pathologic complete remission of metastatic gastrointestinal stromal tumor after imatinib mesylate. J Clin Oncol 23:1580CrossRefPubMedGoogle Scholar
  53. 53.
    Bauer S, Hartmann JT, de Wit M, Lang H, Grabellus F, Antoch G, Niebel W, Erhard J, Ebeling P, Zeth M, Taeger G, Seeber S, Flasshove M, Schütte J (2005) Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer 117:316CrossRefPubMedGoogle Scholar
  54. 54.
    Van den Abbeele AD (2008) The lessons of GIST–PET and PET/CT: a new paradigm for imaging. Oncologist 13(Suppl 2):8–13. doi: 10.1634/theoncologist.13-S2-8 CrossRefPubMedGoogle Scholar
  55. 55.
    Kee D, Zalcberg JR (2012) Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumors. Ther Adv Med Oncol 4:255–270CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Hasegawa J, Kanda T, Hirota S, Fukuda M, Nishitani A, Takahashi T, Kurosaki I, Tsutsui S, Hatakeyama K, Nishida T (2007) Surgical interventions for focal progression of advanced gastrointestinal stromal tumors during imatinib therapy. Int J Clin Oncol 12:212–217CrossRefPubMedGoogle Scholar
  57. 57.
    Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G, Rahman A, Chen G, Staten A, Griebel D (2002) Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 8:3034–3038PubMedGoogle Scholar
  58. 58.
    Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY (2009) Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4):64PubMedGoogle Scholar
  59. 59.
    Reid T (2013) Reintroduction of imatinib in GIST. J Gastrointest Cancer 44(4):385–392CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Demetri GD, van Oosterom AT, Garrett CR, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329CrossRefPubMedGoogle Scholar
  61. 61.
    Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, Badalamenti G, Blackstein M, Le Cesne A, Schöffski P, Maki RG, Bauer S, Nguyen BB, Xu J, Nishida T, Chung J, Kappeler C, Kuss I, Laurent D, Casali PG, GRID study investigators (2013) Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:295–302CrossRefPubMedGoogle Scholar
  62. 62.
    Kang YK, Ryu MH, Yoo C, Ryoo BY, Kim HJ, Lee JJ, Nam BH, Ramaiya N, Jagannathan J, Demetri GD (2013) Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol 14:1175–1182CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Blackstein ME, Blay JY, Corless C, Driman DK, Riddell R, Soulières D, Swallow CJ, Verma S, Canadian Advisory Committee on GIST (2006) Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment. Can J Gastroenterol 20:157CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Royal Academy of Medicine in Ireland 2016

Authors and Affiliations

  • G. A. Watson
    • 1
  • D. Kelly
    • 1
  • M. Melland-Smith
    • 1
  • J. Gleeson
    • 1
  • G. McEntee
    • 2
  • C. M. Kelly
    • 1
  • J. A. McCaffrey
    • 1
  1. 1.Department of Medical OncologyMater Misericordiae University HospitalDublin 7Ireland
  2. 2.Department of SurgeryMater Misericordiae University HospitalDublin 7Ireland

Personalised recommendations